# A computational effort to untangling anti-SARS-CoV-2 effects of oleanolic acid analogues

# Layth Jasim Mohammed<sup>1</sup>, Isaac Karimi<sup>2\*</sup>, Jasim Mohammed Abdulhussein<sup>3</sup>, Ahmed M Sayed<sup>4</sup>, Zuhair Mohammed Ali Jeddoa<sup>5</sup>, Sabrean F Jawad<sup>6</sup>, Mazin AA Najm<sup>7</sup>, Majid S. Jabir<sup>8</sup> and Benine Chaima<sup>9</sup>

<sup>1</sup>Department of Microbiology, Faculty of Medicine, University of Babylon, Hilla City, Babylon Governorate, Iraq.

<sup>2</sup>Laboratory for Computational Physiology, Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran.

<sup>3</sup>Department of Chemistry, Faculty of Medicine, University of Babylon, Hilla City, Babylon Governorate, Iraq.

<sup>4</sup>Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.

<sup>5</sup>Department of Basic Sciences, College of Pharmacy, Al-Zahraa University for Women, Iraq.

<sup>6</sup>Department of Pharmacy, Al-Mustaqbal University College, Hillah, Babylon, Iraq.

<sup>7</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq.

<sup>8</sup>Division of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.

<sup>9</sup>Department of Cellular and Molecular Biology, Faculty of Life and Natural Science, University of El Oued, Algeria.

**Abstract**: Considering the current global pandemic and the urgent need to introduce novel drug candidates against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), we reported at least four antipyretic recipes of Kurdish ethnomedicine which can be translated to functional antiviral formulations in orthodox medicine (Mohammed *et al.*, 2020). Our current demanding computational work places much emphasis upon the implications of oleanolic acid and its analogues as a cluster of binder candidates of the main protease (M<sup>pro</sup>) of SARS-CoV-2 which having a pivotal role in the pathogenesis of coronavirus disease 2019 (COVID-19). Through molecular docking and simulation studies, we found oleanolic acid (-12.6 Kcal/mol) and its two analogues (OA11; ligand I (-14.2 Kcal/mol)) and (OA31; ligand II (-14.0 Kcal/mol)) bound with M<sup>pro</sup> (PDB: 6Y84) more reliable and trustful than saquinavir (-8.1 Kcal/mol) as a canonical drug. Salaspermic acid, (3b)-3-{[(2E)-3-phenylprop-2-enoyl]oxy}olean-12-en-28-oic acid, OA37 and OA40 interacted with catalytic dyad and major amino acid residues of active sites of M<sup>pro</sup> and these toxic compounds should be considered in future anti-protease drug design. Overall, the current study seized the attention of experimentalists to the new set of anti-protease pentacyclic triterpenoids that should to be assayed against SARS-CoV-2 at *in vitro* or in clinical settings of COVID-19.

Keywords: Main Protease; Mpro; COVID-19; oleanolic; acid toxicity; computational biology

Submitted on 19-01-2023 – Revised on 15-10-2023 – Accepted on 31-10-2023

# **INTRODUCTION**

From December 2019, the world faced with the emergence of a newly-evolved strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which has left an indelible mark upon all aspects of life across the world. The corona-virus disease 2019 (COVID-19) pandemic showed a multisurge pattern caused by SARS-CoV-2 variants classified as variants of interest, concern and high consequences (Brief, 2020, Nikhra, 2021). The fatality rate of COVID-19 tends to increase during cold weather that may be different to seasonal influenza (Mecenas, Bastos et al., 2020, Van Asten, Harmsen et al., 2021) and common cold (Aghbash, Eslami et al., 2021). Although, the global vaccination against COVID-19 has progressively been performed, millions of people are still unvaccinated due to poor vaccination coverage in many areas such as poor, populous and developing countries (Gianfredi, Pennisi et al., 2021, Voigt, Nahimana et al., 2021).

Pak. J. Pharm. Sci., Vol.38, No.3, May-June 2025, pp.1039-1060

In any way, our neighbors in the society may be infected and may infect vaccinated or unvaccinated subjects easily due to increased transmissibility of SARS-CoV-2 (Redmond, Jones et al., 2022). As a result, identification or development of anti-viral therapeutic agents and remedies being able to exert therapeutic or prophylactic effects on COVID-19 (especially long form) must be taken into consideration as alternative to available vaccines (Villamagna, Gore et al., 2020). Considerably, Kurdish ethnomedicine is a historical heritage belonging to Kurds providing us with an array of phytomedicines, phytobiotics, functional foods, functional teas and functional formulations extensively applied to treat or to prevent numerous pathological conditions such as infectious diseases (Ahmed, 2016). Recently, a large number of *in silico* investigations along with experimental efforts reported some drug- and lead-like compounds possibly possessing potent anti-COVID-19 efficacy (Ali and Kunugi, 2021, Khanal, Chikhale et al., 2022) but the contagious and life-threatening nature of COVID-19 prevents practitioners from routinely assaying compounds in experiments conducted at both in vitro and in vivo

<sup>\*</sup>Corresponding author: e-mail: karimiisaac@razi.ac.ir

levels. Fortunately, the advancement in computational pharmacology and toxicology can accelerate the process of seeking efficient and potent remedies and reduce the cost of conventional experimentation (Fabbri, Righini et al., 2020, Xiao, Tian et al., 2018). In this essence, U.S. Patent. No. 5,178,865 discloses an experimental treatment with 56 herbs and reported that 10 out of 56 herbs exhibited inhibitorv effect against human immunodeficiency virus (HIV) in the in vitro experiments (Acton, 2013, Chepkwony, Medina et al., 2012). These 10 herbs were Coptis chineusis, Ligusticum wallichii, Ilicium eanclolatum, Isatis tinctoria, Salvia miltiorrhiza, Erycibe obtusifolia, Acanthopanax graciliatylus, Bostaurus domesticus, Inula helenium and Lonicera japonica (Chepkwony, Medina et al., 2012). Both Bostaurus domesticus and Lonicera japonica plus Scutellaria baicaleusis exhibited strong anti-HIV activity (Hung, Lee et al., 2014, Shi, Ren et al., 2016).

In the same way, U.S. Patent. No. 5,837, 257 reported that Chinese herbal medicines exhibit anti-viral activity against murine leukemia virus and HIV which was confirmed through *in vitro* studies. As other instances, Chinese herbal antiviral medicines including hedyotis, *Prunellae spica*, *Lonicera flos*, *Scutellaria barbatae herba*, and *Solani harba* have been reported (Wu, 2004). Accordingly, the present study was aimed at computational discovery of possible antiviral properties of herbal remedies used as antipyretic or anti-flu in Kurdish ethno-medicine and it we tried to identify potential anti-COVID-19 lead-like compounds.

In this regard, fenugreek (*Trigonella foenum-graecum*), chamomile (*Matricaria chamomilla*), sage (*Salvia officinalis*) and zingiber (*Zingiber officinale*) have been proposed in various (sole or supplementary) formulations for COVID-19 prophylaxis and therapy in Kurdish ethnomedicine (for a review see (Mohammed *et al.*, 2020)). According to initial computational effort, oleanolic acid (OA) showed the most reliable binding affinity (BA; -12.7 Kcal/mol) against SARS-CoV-2 3C-like protease (M<sup>pro</sup>) among an array of phytocompounds reported in aforementioned plants.

Oleanolic acid, a pentacyclic triterpene (PT), was considered the hit molecule of our first computational effort and here we placed our concentration upon OA and its analogues reported in a seminal paper (Khwaza, Oyedeji et al., 2018), in order to provide an insightful path to discover anti-SARS-CoV-2 drug- or lead-like compounds. Eventually, multiple studies introduced a number of phytocompounds which may be curative or prophylactic to febrile flu-like conditions occurred in common cold and COVID-19 (AbrahamDogo, Uchechukwu et al., 2020, Matondo, Kilembe et al., 2021, Pawełczyk and Zaprutko, 2020). In a broad view, this study puts forth a great deal of effort to provide a

methodological guide on how future pandemics can be managed with the help of ethnopharmacology.

# MARTIALS AND METHODS

This study has been focused on the widely used computational tools like molecular docking, molecular dynamics and simulations for the identification of possible binders to SARS-CoV-2 main protease (M<sup>pro</sup>). The notable steps utilized in the current study has been depicted in fig. 1.

### Preparation of target M<sup>pro</sup> and 42 Analogues of OA

The X-ray crystal structure of M<sup>pro</sup> was retrieved from PDB Research Collaboratory for Structural Bioinformatics database (http://www.RCSB.org) with ID: 6Y84. It consists of two chains (A and B) containing 309 amino acids with 1.39 Å reported resolution. Alternatively, the chemical structure of OA and its analogues have been curated from PubChem database (https://pubchem.ncbi.nlm.nih.gov/), Drug Bank *ver*: 5.0 (https://www.drugbank.ca/) or drawn using ChemDraw program *ver*: 15.7.13.0 as needed to build up a personal dataset (see fig. 2).

#### Preparation of binders and protein

The target protein, M<sup>pro</sup> (PDB: 6Y84), have been prepared using Molegro Virtual Docker (Thomsen and Christensen, Chimera 1.8.1 2006) and (http://www.rbvi.ucsf. edu/chimera) before trying docking step. The computational molecular docking of phytocompounds (vide supra) and druggable protein M<sup>pro</sup> was accomplished by VINA WIZARD module launched on PyRx programming adaptation 0.8 (Dallakyan and Olson, 2015). The study revealed the final score of sub-atomic docking expressed in BA (Kcal/mol) for a set of docked molecule poses. The maximum exhaustiveness (n = 80)was calculated for each ligands and maximum VINA search space has been selected for docking box to cover whole protein and accommodate ligand to search freely and hit the best binding site in PyRx.

The ligand-protein interaction in VINA WIZARD has been scored based on the estimated ligand-protein free energy of the binding (BA,  $\Delta G$ , Kcal/mol). The binders possessing the strongest BA for 6Y84 were submitted to molecular dynamics (vide infra). The best posed ligands docked with 6Y84 were prepared using Chimera 1.8.1 (http://www.rbvi.ucsf. edu/chimera) and Molegro Virtual Docker (Thomsen and Christensen, 2006). These computational tools have also been employed to prepare protein and library files. The pose docking analysis and graphical interface of shortlisted compounds with Mpro were dissected using LigPlot<sup>+</sup> programming to recognize amino acid residues which are involved in the chemical interactions (Laskowski and Swindells. 2011). Conventionally, the binders that demonstrated BA less than -7.0 Kcal/mol were identified as reliable binders with M<sup>pro</sup> and were discussed (vide infra).

#### Analysis of pharmaco- and toxico-kinetic parameters

Physico-chemical properties and computational descriptors of absorption, distribution, metabolism and excretion (ADME) for acknowledged compounds were evaluated using Swiss ADME program (http://www. swissadme.ch/). This online tool precisely predicts a plethora of pharmaco-kinetic properties including dissolvability, log P, pKa and cytochrome P450 (CYP) interaction and offers violations of Lipinski's rule of five to predict drug-likeness of binders of interest (Lipinski, Lombardo et al., 1997). Furthermore, Toxtree software platform v2.5.1 (http://toxtree.sourceforge.net/) was employed to predict the toxicity class of phytocompounds when administered orally based on their molecular structure (Abdulhussein, Karimi et al., 2021). In this scenario, there exist low (class I) substances with simple chemical structures which efficient metabolic modes exist for them, suggesting a low order of oral toxicity.

Fifth percentile NOEL (no observable effect level; mg/kg body weight/day) of 3.0 and human exposure threshold (mg/person/day) of 1.8 were considered for this class; intermediate (class II) substances possessing structures which are less innocuous compared to class I substances, but not containing structural features suggestive of toxicity like those substances in class III. Fifth percentile NOEL (mg/kg body weight /day) of 0.91 and human exposure threshold (mg/person/day) of 0.54 were considered for this class; and high (class III) substances with chemical structures permitting no strong initial presumption of safety or may even suggest significant toxicity or have reactive functional groups. Fifth percentile NOEL (mg/kg body weight /day) of 0.15 and human exposure threshold (mg/person/day) of 0.09 were considered for this class (Cramer, Ford et al., 1976, Munro, Ford et al., 1996, Patlewicz, Jeliazkova et al., 2008).

# Molecular dynamics (MD) studies and trajectories analysis

The stability and movement of top-ranked OA analogues possessed the strongest BA with  $M^{pro}$  were evaluated through MD simulation using the GROMACS 2018.8 package (Van Der Spoel, Lindahl *et al.*, 2005) and employing the CHARMM36 force field (Best, Zhu *et al.*, 2012). The conformers with the fittest and lowest docking energy were selected for validation of initial complex interactions. Complete simulation system was placed in a dodecahedron box and water molecules were added using a simple point charge model (Rivail, Chipot *et al.*, 2007). To ensure the overall charge neutrality of the simulated system, sufficient amount of Na<sup>+</sup> counter-ions were added with periodic boundary conditions applied in all three directions of space.

The force field parameters of ligands were achieved from CGenFF web server (https://cgenff.umaryland.edu/) (Vanommeslaeghe and MacKerell Jr, 2012). Initially, Pak. J. Pharm. Sci., Vol.38, No.3, May-June 2025, pp.1039-1060

energy minimization of complex was achieved using the steepest descent method (Hess, Kutzner *et al.*, 2008). The procedure of position restraint was accomplished in both NVT and NPT ensembles after energy minimization. The first phase of equilibration involved simulating for 1 ns under the canonical ensemble (NVT) followed by a 1 ns NPT equilibration. The temperature was maintained at 300 °K with the Nose–Hoover thermostat (Hoover, 1985, Nosé, 1984, Nosé and Klein, 1983). The NPT equilibration was performed using the Parrinello-Rahman barostat (Parrinello and Rahman, 1981) to maintain a constant pressure of 1.0bar.

In this study, the Lennard-Jones potential with 1.0-nm cutoff, particle mesh Ewald method with 1.0-nm cutoff (Darden, York *et al.*, 1993, Essmann, Perera *et al.*, 1995), and the Lincs algorithm (Hess, Bekker *et al.*, 1997) were used for van der Waals interactions, long range electrostatics, and covalent bond constraints, respectively. Finally, 100 ns MD simulations was performed to analyze the trajectories using the leap-frog algorithm and solve the equations of motion with a time step of 2 fs.

#### RESULTS

#### Molecular docking analysis

Docking study has been pursued to analyze the binding interaction of OA and its analogues to M<sup>pro</sup> and to predict the general binding modes of ligand for determining the residues of protein which were involved in ligand binding. It has been highlighted that the crucial amino acids of M<sup>pro</sup> were involved in the stable interaction of respective ligands or control ligand, saquinavir, as a canonical protease inhibitor, with their predicted BAs. The obtained results with respective binding scores and class of toxicity were presented in table 1.



**Fig. 1**: Workflow of cheminformatics of SARS-CoV-2 main protease and oleanolic acid analogues applied in the current study





**Fig. 3**: The *in silico* molecular docking of oleanolic acid and its analogues (*in yellow*) against main protease of SARS-CoV-2 (PDB 6Y84; *in cyan*)



A computational effort to untangling anti-SARS-CoV-2 effects of oleanolic acid analogues

**Fig. 4**: RMSDs of SARS-CoV-2 M<sup>pro</sup> in the ligand-free form and in the presence of oleanolic acid, ligand I, ligand II and saquinavir.



**Fig. 5**: RMSDs of oleanolic acid, ligand I and ligand II and saquinavir inside the active site of SARS CoV-2 M<sup>pro</sup> Over the course of 100 ns-long MD simulation. OA showed the lowest average RMSD (~0.05nm) and the most stable binding inside the active site of M<sup>pro</sup>, while ligand 2 was the least stable ligand with an average RMSD of 0.21 nm over the simulation time. The RMSD profiles of both ligand 1 and saquinavir were convergent with an average of ~ 0.09 nm.



Fig. 6: Time dependence of the Rg of the protein during the simulation for free and bound SARS-CoV-2 main protease



Fig. 7: RMSF of residues of protein from their time averaged positions during last 20 ns for free and bound SARS-CoV-2 main protease



**Fig. 8**: Variation of the secondary structure versus time for the protein in the presence of a) Oleanolic acid, b) ligand I and c) ligand II



**Fig. 9**: Time dependence of total number of hydrogen bonds between protein and a) Oleanolic acid, b) ligand I and c) ligand II

Ligands No.	Canonical SMILES	Binding affinity (Kcal/mol)	RMSD/upper bound	RMSD/lower bound	Toxicity class/ Chemical feature
Oleanane-9548717	7 CC1(CCC2(CCC3(C(C2C1	· · · · ·			Low (Class I); common
(OA1)	)CCC4C3(CCC5C4(CCCC	-13.2	2.385	0.714	terpene
()	5(C)C)C)C)C)C)C				
Ursane-9548870	CC1CCC2(CCC3(C(C2C1				Low (Class I); common
(OA2)	C)CCC4C3(CCC5C4(CCC	-13.3	5.717	0.521	terpene
(0A2)	C5(C)C)C)C)C)C	-15.5	5.717	0.521	terpene
Est datas					L (Classe I).
Friedelane-	CC1CCC2C1(CCC3C2(C	12.0		0.540	Low (Class I); common
15559345 (OA3)	CC4(C3(CCC5(C4CC(CC5	-13.2	5.775	0.549	terpene
	)(C)C)C)C)C)C)C				
Hopane-10115	CC(C)C1CCC2(C1CCC3(C				Low (Class I); common
(OA4)	2CCC4C3(CCC5C4(CCCC	-11.0	32.5	29.78	terpene
	5(C)C)C)C)C)C				
Lupane ChemDrav	wCC(C)[C@@H]1CC[C@]2				High (Class III); The
(OA5)	(C)CC[C@]3(C)C(CCC4[C	-10.3	22.361	17.175	lack of sufficient
	@@]5(C)CC[C@H](C)C(C	-10.3	22.301	17.175	number of sulphonate or
	)(C)C5CC[C@@]34C)C12				sulphamate groups
Gammacerane-	CC1(CCCC2(C1CCC3(C2				High (Class III); The
9548720 (OA6)	CCC4C3(CCC5C4(CCCC5				lack of sufficient
<i>))10120</i> (0 <i>110)</i>	(C)C)C)C)C)C)C	-13.8	5.279	0.059	number of sulphonate or
					sulphamate groups
Cluormhizia agid	1-CC1(C2CCC3(C(C2(CCC1				
					High (Class III); The
14982 (OA7)	OC4C(C(C(C(O4)C(=O)O)				lack of sufficient
	0)0)0C5C(C(C(C(05)C(=	-10.8	9.905	3.332	number of sulphonate or
	O)O)O)O)O)C)C(=O)C=C6				sulphamate groups;
	C3(CCC7(C6CC(CC7)(C)C				Heterocyclic
	(=O)O)C)C)C)C				
Salaspermic acid	-CC1C23CCC4C(C2CCC1(				High (Class III); The
44593364 (OA8)	OC3)O)(CCC5(C4(CCC6(				lack of sufficient
	C5CC(CC6)(C)C(=O)O)C)	-12.5	32.799	32.307	number of sulphonate or
	C)C)C				sulphamate groups;
	, ,				Heterocyclic
Betulinic acid	l-CC(=C)C1CCC2(C1C3CC				Low (Class I); common
64971 (OA9)	C4C5(CCC(C(C5CCC4(C3				terpene
01071 (0110)	(CC2)C)C)(C)C)O)C)C(=O	-11.8	33.309	32.521	terpene
	)0				
Oleanolic acid	1-CC1(CCC2(CCC3(C(=CC				Low (Class I); common
10494 (OA10)	C4C3(CCC5C4(CCC(C5(C				
10494 (OA10)		-12.6	6.19	0.869	terpene
	)C)O)C)C)C2C1)C)C(=O)				
	3-[H][C@@]12CC(C)(C)CC[				Low (Class I); Open
	cC@@]1(CC[C@]1(C)C2=				chain; Aliphatic with
acid-ChemDraw	CC[C@]2([H])[C@@]3(C)	-14.2	5.581	1.322	some functional groups
(OA11)	CC[C@H](OC(C)=O)C(C)(	-14.2	5.561	1.522	
	C)[C@]3([H])CC[C@@]12				
	C)C(=O)OC				
3-acetoxyoleanolic	: [H]OC(=O)[C@]12CCC(C)				Low (Class I) or
acid-ChemDraw	(C)C[C@@]1([H])C1=CC[				Class Intermediate
(OA12)	C@]3([H])[C@@]4(C)CC[				(Class II); Readily
()	C@H](OC(C)=O)C(C)(C)[	-10.6	35.265	33.868	hydrolysed to a
	C@]4([H])CC[C@@]3(C)[	10.0	55.205	55.000	common terpene; Open
	C@]1(C)CC2				chain; Aliphatic with
					some functional groups
					some functional groups

Table 1: Molecular docking results of oleanolic acid and its analogues with protease (PDB: 6Y84) of SARS-CoV-2 and their toxicity class

Continue...

(3b)-3-{[(2E)-3-	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
phenylprop-2-	@@]1(CC[C@]1(C)C2=CC[C				sufficient number of
enoyl]oxy}olean-	@]2([H])[C@@]3(C)CC[C@	10.2	20.020	25 120	sulphonate or sulphamate
	$H^{-H}(OC4=CC=C(C=C)C=O)C$	-10.2	28.939	25.139	groups; Aromatic; Rings with
	=C4)C(C)(C)C3([H])CC[C@				substituents; Aromatic Ring
	@]12C)C(O)=O				with complex substituents
(3b)-3-ethoxyolean	- [H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
	1-@@]1(CC[C@]1(C)C2=CC[C]				sufficient number of
	) @]2([H])[C@@]3(C)CC[C@	-10.7	33.516	31.734	sulphonate or sulphamate
	H](OCC)C(C)(C)C3([H])CC[				groups
	C@@]12C)C(O)=O				8 1
OA15-ChemDraw	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
-	aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa				sufficient number of
	@]2([H])[C@@]3(C)CC[C@	10.0		• • • • •	sulphonate or sulphamate
	H](OC(=O)C4=CC=CS4)C(C)	-10.2	9.099	3.069	groups; Heterocyclic and
	(C)[C@]3([H])CC[C@@]12C				Heteroaromatic with the ring
	)C(0)=O				bear any substituents
OA16-ChemDraw	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
	@@]1(CC[C@]1(C)C2=CC[C				sufficient number of
	@]2([H])[C@@]3(C)CC[C@				sulphonate or sulphamate
	H](OC(=0)C(Cl)C4=CC=CC=	-10.0	9.643	3.34	groups; Contains elements
	C4)C(C)(C)[C@]3([H])CC[C				other than C,H,O,N, divalent S
	(a)(a)(1)C(0)(0)(0)=0				
OA17-ChemDraw	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
O/II/-Chemblaw	@@]1(CC[C@]1(C)C2=CC[C				sufficient number of
	@]2([H])[C@@]3(C)CC[C@				sulphonate or sulphamate
	H](OC(=O)C(C)Cl)C(C)(C)[C]	-9.9	8.709	2.89	groups; Contains elements
	a[3([H])CC[C@@]12C)C(O)				other than C,H,O,N, divalent S
	=0				other than C, 11, 0, 14, divalent 5
OA18-ChemDraw	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
OTTO Chembraw	@@]1(CC[C@]1(C)C2=CC[C				sufficient number of
	@]2([H])[C@@]3(C)CC[C@				sulphonate or sulphamate
	H](OC(=O)C(Cl)Cl)C(C)(C)[C]				groups; Contains elements
	@]3([H])CC[C@@]12C)C(O)	-10.0	8.715	3.652	other than C,H,O,N, divalent
	=0				S and elements not listed in
	5				Q3 occurs only as a
					Na,K,Ca,Mg,N salt.
OA19-ChemDraw	[H][C@@]12CC(C)(C)CC[C				High (Class III); The lack of
OTT) Chembruw	@@]1(CC[C@]1(C)C2=CC[C				sufficient number of
	@]2([H])[C@@]3(C)CC[C@				sulphonate or sulphamate
	H](OC(=O)C(Cl)Cl)C(C)(C)[C]				groups; Contains elements
	@]3([H])CC[C@@]12C)C(O)	-10.0	8.718	3.635	other than C,H,O,N, divalent S
	=0				and elements not listed in Q3
	0				occurs only as a
					Na,K,Ca,Mg,N salt.
OA20-ChemDraw	[H][C@@]12CC(C)(C)CC[C				Class Low (Class I); readily
0/120 Chembluw	@@]1(CC[C@]1(C)C2=CC[C				hydrolysed to a common
	@]2([H])[C@@]3(C)CC[C@				terpene; Class Intermediate
	$H_{OC}^{(11)}(CC_{O}^{(11)}(CC_{O}^{(11)}))$	-9.5	9.203	2.575	(Class II); Open chain;
	C[C@]3([H])CC[C@@]12C)				Aliphatic with some functional
	C(0)=0				groups
OA21-ChemDraw	[H]C1C[C@]2(C)[C@]([H])(C				High (Class III); The lack of
UA21-CICIIDIAW	C=C3[C@]4([H])CC(C)(C)C[				sufficient number of
	$C=C_{3}[C_{a}]_{4}(CC[C_{a}]_{2}]_{2}C(C)(C)C_{1}$				sulphonate or sulphamate
	=O[C@@]2(C)CC[C@H](O	-10.7	37.861	23.651	groups; Heterocyclic
	C(=0)C3C4CC(C=C4)C3C(0)				groups, meterocyclic
	=0)C(C)(C)C12				

OA22 -	[H][C@@]12CC(C)(C)CC[C@				Class Low (Class I); Readily
ChemDraw	@]1(CC[C@]1(C)C2=CC[C@] 2([H])[C@@]3(C)CC[C@H](O C(=O)C4=CC=CC=C4C(O)=O )C(C)(C)[C@]3([H])CC[C@@	-10.7	2.957	1.805	hydrolysed to a common terpene; Class Intermediate (Class II); Aromatic rings with substituents
OA23- ChemDraw	]12C)C(O)=O [H][C@@]12CC(C)(C)CC[C@ @]1(CC[C@]1(C)C2=CC[C@] 2([H])[C@@]3(C)CC[C@H](O C(=O)\C=C\C(O)=O)C(C)(C)[ C@]3([H])CC[C@@]12C)C(O )=O	-9.9	11.862	2.52	Class Low (Class I); Class Intermediate (Class II); Open chain; Aliphatic with some functional groups
OA24- ChemDraw	)-O [H][C@@]12CC(C)(C)CC[C@ @]1(CC[C@]1(C)C2=CC[C@] 2([H])[C@@]3(C)CC[C@H](O C(=O)\C=C(/C)C(O)=O)C(C)( C)[C@]3([H])CC[C@@]12C) C(O)=O	-9.1	9.676	2.288	Class Low (Class I); Readily hydrolysed to a common terpene; Class Intermediate (Class II); Aromatic rings with substituents; Open chain
OA25- ChemDraw	[H][C@]12CCC3[C@@]4(C)CC[C@H](O)C(C)(C)C4CC[C@@]3(C)[C@]1(C)CC[C@]1(CCC(C)(C)C[C@@]21[H])C(O)=O	-9.7	29.338	24.921	Low (Class I); common terpene
OA26- ChemDraw	[H][C@]12CCC3[C@@]4(C)C C[C@H](OCC(=O)CC(C)(C)C C(O)=O)C(C)(C)C4CC[C@@] 3(C)[C@]1(C)CC[C@]1(CCC(	-9.4	28.584	23.546	High (Class III); The lack of sufficient number of sulphonate or sulphamate groups
OA27- ChemDraw	C)(C)C[C@@]21[H])C(O)=O [H][C@]12CCC3[C@@]4(C)C C[C@H](OCC(=O)CC5(CCCC C5)C(O)=O)C(C)(C)C4CC[C@ @]3(C)[C@]1(C)CC[C@]1(CC C(C)(C)C[C@@]21[H])C(O)= $\hat{C}$	-10.3	11.937	2.147	High (Class III); The lack of sufficient number of sulphonate or sulphamate groups
OA28- ChemDraw	O [H][C@]12CCC3[C@@]4(C)C C[C@H](OCC(=O)CC(C)(C)C (O)=O)C(C)(C)C4CC[C@@]3( C)[C@]1(C)CC[C@]1(CCC(C) (C)C[C@@]21[H])C(O)=O	-9.6	1.412	1.182	High (Class III); The lack of sufficient number of sulphonate or sulphamate groups
OA29- ChemDraw	[H][C@@]12CC(C)(C)CC[C@ ]1(CNCC(=0)CC(C)(C)CC(O) =0)CC[C@]1(C)C2=CCC2[C @@]3(C)CC[C@H](OCC(=0) CC(C)(C)CC(O)=0)C(C)(C)C3	-9.4	1.647	1.211	High (Class III); The lack of sufficient number of sulphonate or sulphamate groups
OA30- ChemDraw	CC[C@@]12C [H][C@@]12CC(C)(C)CC[C@ ]1(CNCC(=0)CC1(CC(0)=0) CCCC1)CC[C@]1(C)C2=CCC 2[C@@]3(C)CC[C@H](OCC( =0)CC4(CC(0)=0)CCCC4)C( C)(C)C2CC[C@@]12C	-10.4	2.181	1.735	High (Class III); The lack of sufficient number of sulphonate or sulphamate groups
OA31- ChemDraw	C)(C)C3CC[C@@]12C [H][C@@]12CC[C@]3(C)C([ H])(CC=C4[C@]5(C)CC(C)(C) C[C@@]5(CC[C@@]34C)C(O) )=O)[C@@]1(C)CC[C@H](O C(=O)OC(=O)CC(C)(C)C(O)= O)C2(C)C	-14.0	1.404	0.966	Class Low (Class I); Readily hydrolysed to a common terpene; Class Intermediate (Class II); Open chain; Common component of food; Aliphatic with some functional groups
					Continue

OA32- ChemDraw	[H][C@@]12CC[C@]3(C)C([ H])(CC=C4[C@]5(C)CC(C)(C)				Class Low (Class I); Readily hydrolysed to a common terpene;
Chembraw	C[C@@]5(CC[C@@]34C)C(O)				Class Intermediate (Class II);
	)=O)[C@@]1(C)CC[C@H](O	-13.8	17.12	14.348	Open chain; Common component
	C(=O)OC(=O)CC(C)(C)CC(O)				of food; Aliphatic with some
	=O)C2(C)C				functional groups
OA33-	CC(=O)N[C@@H]1[C@@H](				High (Class III); The lack of
ChemDraw	O)CC(OCCOC(=O)[C@]23CC				sufficient number of sulphonate
	C(C2C2=CCC4[C@@](C)(CC	-12.3	13.43	10.843	or sulphamate groups;
	C5C(C)(C)[C@@H](O)CC[C	-12.3	15.45	10.045	Heterocyclic with ring with
	@]45C)C2CC3)C(C)=C)OC1C				complex
	(0)C(0)CO				
OA34-	COC(=0)C1(CC(OC(C)=0)C(				High (Class III); The lack of
ChemDraw	NC(=O)N2CC(NC(=O)[C@]34				sufficient number of sulphonate
	CCC(C)(C)CC3C3=CCC5[C@				or sulphamate groups;
	@]6(C)CC[C@H](O)C(C)(C)C	-8.6	15.278	5.867	Heterocyclic ring with complex substituents
	6CC[C@@]5(C)[C@]3(C)C[C @H]4C)N=N2)C(O1)C(OC(C)				substituents
	=0)[C@@H](COC(C)=0)OC(				
	C)=O)OC				
OA35-	COC(=0)C1(CC(OC(C)=0)C(				High (Class III); The lack of
ChemDraw	NC(=O)N2CC(NC(=O)[C@]34				sufficient number of sulphonate
	CC[C@H](C3C3=CCC5[C@@				or sulphamate groups;
	]6(C)CC[C@H](O)C(C)(C)C6		28.046	20.956	Heterocyclic ring with complex
	CC[C@@]5(C)[C@]3(C)C[C	-7.7	28.046	20.856	substituents
	@H]4C)C(C)=C)N=N2)C(O1)				
	C(OC(C)=O)[C@@H](COC(C)				
	=O)OC(C)=O)OC				
OA36-	[H][C@@]12CC[C@]3(C)C(=				High (Class III); The lack of
ChemDraw	CC = C4[C@@]3(C)CC[C@]3(				sufficient number of sulphonate
	CCC(C)(C)C[C@@]43C)C(O)	-10.6	26.352	22.158	or sulphamate groups
	= O)[C@@]1(C)CC[C@H](O)				
OA37-	C2(C)C [H][C@@]12CC[C@@]3(C)[C				High (Class III); The lack of
ChemDraw	@]4(C)CC[C@]5(CC[C@H](C				sufficient number of sulphonate
Chemblaw	C[C@@]5(C)C4=CC(=O)C3(	-9.8	32.38	27.083	or sulphamate groups
	O)[C@@]1(C)CC[C@H](O)C2	2.0	52.50	27.005	or surprantate groups
	(C)C)C(O)=O				
OA38-	[H][C@@]12CC[C@]3(C)C4(				High (Class III); Heterocyclic
ChemDraw	OC4C=C4[C@@]3(C)CC[C@]				
	3(CCC(C)(C)C[C@@]43C)C(	-10.7	26.122	22.013	
	O)=O)[C@@]1(C)CC[C@H](				
	O)C2(C)C				
OA39-	[H][C@@]12CC[C@]3(C)C(=				High (Class III); The lack of
ChemDraw	CC=C4[C@@]3(C)CC[C@]3(				sufficient number of sulphonate
	CCC(C)(C)C[C@@]43C)C(O)	-10.7	26.015	21.892	or sulphamate groups
	=O)[C@@]1(C)CCC(=O)C2(C				
0 1 10					
OA40- ChamDrawy	[H][C@@]12CC[C@@]3(C)[C				High (Class III); The lack of
ChemDraw	@]4(C)CC[C@]5(CCC(C)(C)C	10.6	7 710	1 402	sufficient number of sulphonate
	[C@@]5(C)C4=CC(=O)C3(O)[	-10.6	7.718	1.402	or sulphamate groups
	C@@]1(C)CCC(=O)C2(C)C)C (O)=O				
OA41-	[H][C@@]12CC[C@]3(C)[C@				High (Class III); The lack of
ChemDraw	]([H])(CC=C4[C@@]3(C)CC[				sufficient number of sulphonate
c	C@]3(CCC(C)(C)C[C@@]43C	-10.8	26.326	22.248	or sulphamate groups
	)C(O)=O)[C@@]1(C)CCC(=O)				
	C2(C)C				

A computational effort to untangling anti-SARS-CoV-2 effects of oleanolic acid analogues

Hederagenin	[H][C@@]12CC(C)(C)CC[C@				Low (Class I); common terpene
(OA42)-	@]1(CC[C@]1(C)C2=CC[C@]				
ChemDraw	2([H])[C@@]3(C)CC[C@H](O	-10.2	25.998	21.54	
	)[C@@](C)(CO)[C@]3([H])C				
	C[C@@]12C)C(O)=O				
Saquinavir-	CC(C)(C)NC(=O)C1CC2CCC				High (Class III); The lack of
DrugBank	CC2CN1CC(C(CC3=CC=CC=				sufficient number of sulphonate
-	C3)NC(=O)C(CC(=O)N)NC(=	-8.1	1.433	1.202	or sulphamate groups;
	O)C4=NC5=CC=CC=C5C=C4)				Heterocyclic ring with complex
	0				substituents

RMSD: root mean-square deviation is the measure of the average distance between the atoms. See [21] for more details.

**Table 2**: The chemical dissection of the interactions of oleanalic acid analogues and protease (PDB: 6Y84) of SARS-CoV-2

Ligands No.	Hydrogen bond	Hydrophobic interaction Interacted atoms of ligands	No. in Fig. 2
Oleanane (OA1)	ND	V303, R298, F8, D295, Q127,-	1
		A7, M6, and P9	
Ursane (OA2)	ND	V303, P9, M6, A7, Q127, F8,-	2
		D295, and R298	
Friedelan (OA3)	ND	D298, Q127, A7, F8, P9,-	3
		V303, M6, and D295	
Hopane (OA4)	ND	R298, F8, P9, A7, V303, M6,-	4
		D295 and Q127	
Lupine (OA5)	ND	P9, A7, Met6, R298, Q127,-	5
		Asp295, F8, Q299, V303	
		G302, and T304	
Gammacerane (OA6)	ND	P9, A7, Q127, F8, D295, M6,-	6
		R298, and V303	
Glycyrrhizic acid (OA7)		eT111, A129, N151, I152, S10,O15, O16, O8 with P9 and F8 and	
	with F8	V13, Y126, and M6 O <sub>8</sub> , O <sub>10</sub> with V125 and O <sub>10</sub> , O <sub>11</sub>	,
		C <sub>37</sub> with A7, and O <sub>2</sub> , C <sub>19</sub> , C <sub>1</sub> , C <sub>2</sub>	
		C19, C13 with Q27 and C23, C28	3
		with E290, and $C_{20}$ , $C_{12}$ with	l
		C128 and C6, C7, C25 with F112	
Salaspermic acid (OA8)	R188 and T190	M165, M49, His41, E166,O3 with R188 and O3, O2 with	ı 8
• · · ·		P168, Q189, Q192 and L167 T190	
Betulinic acid (OA9)	Q127and D295	A7, P9, F8, R298, M6, Q299,O3 with Q127 and D295	9
		G302, and V303	
Oleanolic acid (OA10)	D295	P9, M6, F8, A7, R298, Q127,O3	10
		V303, G302 and T304	
3-acetoxy, 28-methyloleanoli	cR298	Q127, D295, M6, V303, P9,O3	11
acid (OA11)		Q299 and F8	
3-acetoxyoleanolic acid (OA12)	M6 and R298	P9, F8, A7, Q127, Q299,O <sub>2</sub> with M6 and O <sub>1</sub> with R298	12
-		D295, V303 and T304	
(3b)-3-{[(2E)-3-phenylprop-2-	T26	T190, Met165, Q192, Met49,O <sub>2</sub>	13
enoyl]oxy}olean-12-en-28-oic		His41, G143, G189, R188,	
acid (OA13)		E166 and P168	
(3b)-3-ethoxyolean-12-en-28-oic	R298	T304, P9, A7, F8, M6, D295,O <sub>1</sub>	14
acid (OA14)		Q127, Q299, V303, and 302	
OA15	D289	272, Y239, Y237, Thr199,O <sub>2</sub>	15
		R131, D197, E290, K137,	
		L286 and L287	
OA16	D131, L272 an	dD197, Ala285, T199, G275,O2 with L272, and l271 and O.	16
	L271	Y237, L287, L287, E288 and with D131	
		D289	
OA17	D289	L272, Tyr237, Y239, Thr199,O <sub>2</sub>	17
	~~	D197, R131, E290, Y137,	
		L286, M276, G275 and L271	

Continue...

80A18	ND	L272, Y237, Y239, Thr199,-	18
		D197, K137, E290, Arg131,	
0.4.10	D290	L286, L287 and Leu271	10
OA19	D289	L271, L272, Y239, Tyr237,O <sub>2</sub>	19
		T199, D197, R131, Lys137,	
0 4 20	ND	E290, L286, L287 and G275	20
OA20	ND	Y237, Y239, T199, Asp197,-	20
		R131, E290, K137, L286,	
0421	D290	L287, L271 and L272	21
OA21	D289	L272, Y239, Y237, T199,O <sub>2</sub>	21
		R131, D197, K137, E290,	
0 4 2 2	D290	E288, L286, L287 and L271	22
OA22	D289	L271, Tyr237, Y239, L272, $O_2$	22
		T199, Asp197, K137, E288	
		E290, Arg131, Leu286 and	
a 4 <b>a a</b>	<b>Da</b> 000 1117	L287	
OA23	D289 and K5	Y239, TY237, L272, Thr199, O <sub>2</sub> with D289 and O <sub>4</sub> with K5	23
		Asp197, R131, E290, K137,	
		L286, G275, L287 and L271	
OA24	K5 and D289	L271, L272, Y137, Y239,O <sub>2</sub> with D289 and O <sub>2</sub> , O <sub>4</sub> with K5	24
		T199, Arg131, D197, E290,	
		K137, L286, M276, L287	
		and G275	
OA25	T199, R131, D19	07Y237, L272, L287, L286,O1	25
		D289, and T198	
OA26	L287 and T199	K5, K137, E290, R131,O <sub>3</sub> with L287 and O <sub>4</sub> with T199	26
		D197, Y137, Y239, L272,	
		L286 and G288	
OA27	ND	L272, Leu287, 286, E288,-	27
		K5, Q127, C128, Tyr126,	
		E290, K137, D289, R131,	
		Y239 and T199	
OA28	K5	L271, L272, Y237, T199,O <sub>2</sub>	28
		D197, Lys137, R131, E290,	
		E288, L286, M276, L287 and	
		G275	
OA29	K5 and N238	L272, L271, L287, L286,O <sub>5</sub> with K5 and O <sub>3</sub> with N238	29
	110 4110 1 1200	E290, C128, K137, Q127,	
		T199, D197 and Y237	
OA30	· · · · · · · · · · · · · · · · · · ·	7, T99, D197, D289, R131, $O_3$ with Y237 and $O_1$ with L287,	30
	Y239, K5 ar	ad E290, L286 and L272 and $O_2$ with Y239 and $O_5$ with K5	
	E288	and O <sub>5</sub> with E288	
OA31	Q299	Q127, D295, M6, I152,O <sub>8</sub>	31
		T304, F8, P9, V303, R298	
		and F291	
OA32	Q299	D295, M6, F291, Q127,O8	32
-		R298, P9, I152, F8, T304 and	-
		V303	
OA33	ND	Q299, M6, D295, D127, F8,-	33
		R298, V303 and G302	
OA34	Q127, E290 ar	nd T199, L287, L286, E288, K5, O <sub>8</sub> , O <sub>16</sub> with E290 and N <sub>5</sub> with	34
	D289	G138, C128, Y126, K137,D289	
		D197, R131, L272 and Y237	
OA35	K100 and S158	F103, cys156, P99 F159 and O <sub>2</sub> , C <sub>3</sub> with K100 and C <sub>3</sub> , C <sub>19</sub> with	35
		R105 S158	
OA36	D295 and R298	T304, P9, V303, M6, A7, F8,O3	36
	2 270 und 1(2)0	Q290 and G302	20
		X710 min 0107	
			Continue

OA37	T25, E189 and	Y45, S46, M49, Q189,O5 with E189 and O4 with N14	2 37
	N142	M165, C145 (Cys145), T24 and O2 with T25	
		and T26	
OA38	L272, L271 and	D289, D197, Y198, Y237, O4 with L272, L271 and O2 with	th 38
	T199	Leu287 and Leu286 T199	
OA39	L271 and T199	D197, T198, L287, Tyr237,O <sub>3</sub> with L271 and O <sub>2</sub> with T199	39
		L272 and L286	
OA40	E166 and T25	T45, S46, M149, Q189,O5 with E166 and O2 T25	40
		M165, N142, Cys145, Thr26	
		and Thr24	
OA41	Q299 and D295	T45, S46, M149, Q189,O <sub>5</sub> with Q299 and O <sub>2</sub> with D295	41
		M145, N142, Cys145, Thr26	
		and Thr24	
Hederagenin (OA42)	D295 and M6	F8, Pro9, Q127, A7, R298,O <sub>2</sub> with D295 and O <sub>1</sub> with M6	42
<b>C</b>		Q299, V303, Gly302 and	
		T304	
Saquinavir	ND	T26, His41, M49, M165,ND	saquinavir
		Q189, H163, E166, N142,	
		C145 Cys145) and G143	

Note: ND: not detected

#### ADME analysis

The classes of toxicity which OA analogues belonged showed considerable variation. In this context, analogues 16, 6 and 15 were belonged to the low (Class I), low (Class I) or intermediate (Class II) and highly toxic (Class III), respectively. Among low (Class I) toxic compounds, the strongest BA was reported for OA11 (-14.2) and OA31 (-14.0 Kcal/mol) and these two ligands were submitted for MD (*vide infra*). In this context, the safest compound was OA11 since OA31 was much closer to intermediate (Class II) toxic compounds. All results of ADME are presented in Supplementary file 2.

#### Molecular docking and trajectories analysis

Molecular docking offers practical binding structures while MD simulation enables us to understand structure and dynamics in detail for further investigation of the binding modes of ligands and explanation. In this study, GROMACS analysis tools were employed to analyze the trajectories in terms of root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration ( $R_g$ ), H-bond frequency, and the secondary structure.

To confirm the stability of simulations, the RMSD of protein in the absence and presence of OA, ligand I, ligand II and saquinavir were analyzed during 100 ns simulation time. The result highlighted that these compounds remain in a stable binding position with low RMSD fluctuations which confirms the feasibility of binding poses predicted by AutoDock. The mean RMSD values for protein, protein in complex with the OA, ligand I, ligand II and saquinavir were 0.267 nm, 0.238 nm, 0.215 nm and 0.225 nm, respectively (fig. 4,5). The highest value of mean RMSD for SARS-CoV-2 M<sup>pro</sup> represents the formation of stable complexes of this protein with these compounds. Moreover, the lowest value of mean RMSD for protein in complex with ligand I signifies the formation of most stable complex of protein with this compound.

According to structure-based drug discovery, the modes of interaction between ligands and target protein(s) give us strong cues to screen better hits. Accordingly, the types of interaction and atoms of ligands and amino acid residues of  $M^{pro}$  have been summarized in table 2, fig. 3 and Supplementary file 1. The BAs of OA analogues showed a range of -7.7 (OA35) to -14.2 (0A11) Kcal/mol. Surprisingly, most of the OA analogues showed acceptable and reliable BAs with  $M^{pro}$  ( $\leq$ -10 Kcal/mol; table 1).

The compactness of protein structure during MD simulation time was assessed by analysis of the radius of gyration ( $R_g$ ). As illustrated in fig. 6, the  $R_g$  of SARS-CoV-2 M<sup>pro</sup> decreased with binding of all three compounds implying a more compact structure of this protein after simulations.

The RMSF analysis of SARS-CoV-2 M<sup>pro</sup> in the absence and presence of OA, ligand I and ligand II can be used as a reference value to estimate the flexibility of the residues (fig. 7). The results produced by RMSF analysis of protein during the last 20 ns indicated that main fluctuations (> 0.2 nm) correspond to residues belonging to the mobile loops of protein which are far from the ligand binding site. In contrast, residues which were found to interact with these compounds in the binding site of SARS-CoV-2 M<sup>pro</sup> are among the most stable residues of this protein (RMSF < 0.10 nm).

The secondary structure of the protein was calculated with the DSSP code of GROMACS. Fig. 8 shows the  $\alpha$ -helix,  $\beta$ -Sheet and other secondary structures of the protein in three simulations. As demonstrated in this fig. 8, main secondary structures of SARS-CoV-2 M<sup>pro</sup> maintain fair stability during 100 ns MD simulations. Therefore, the principal conformational change of protein proposed during binding of the OA, ligand I and ligand II is a simple motion.

The total number of hydrogen bonds between SARS-CoV-2 M<sup>pro</sup> and OA, ligand I and ligand II were calculated using the g\_hbond function of GROMACS which, the geometry standard of H-bonds was 0.35 nm for H-accepter distance and 3.0 nm for the donor-H-acceptor angle. The analysis of H-bonds showed that ligand I has more H-bonds compared to those of OA and ligand II which suggests the formation of most stable complex of protein with this compound (fig. 9).

#### DISCUSSION

Many PTs show numerous pharmacological activities and some are even marketed as therapeutic agents or dietary supplements (Siddique and Saleem, 2011). Structurally, PTs have four six membered rings characterized as A, B, C, D plus ring E being five-membered or six-membered structures. Based on the carbon skeleton, they are allocated into six common subgroups: oleanane, lupane, ursane, friedelane, hopane and gammacerane. In this regard, PTs are a large class of secondary plant metabolites constructed by isoprene (2-methylbutadiene; C5H8) units (Ruzicka, 1953, Xiao, Tian *et al.*, 2018)

Oleanane (OA1) is a PT and with its congeners possess anti-viral activity for influenza virus, hepatitis virus, HIV, and porcine epidemic diarrhea virus (Cheng, Wang *et al.*, 2013, Kazakova and Smirnova, 2022, Khwaza, Oyedeji *et al.*, 2018, Su, Meng *et al.*, 2019, Wu, Yang *et al.*, 2016). Moreover, OA1 is known as a modulator of influenza hemagglutinin (HA).

The glycosylated OA intensified the HA inhibitory activity of OA with no overt cytotoxicity upon Madin-Darby canine kidney cells (Orhan and Senol Deniz, 2020, Su, Meng et al., 2019). Ursane (OA2) belongs to PTs and it has anti-inflammatory, anti-microbial, cytotoxic, hepatoprotective and anti-tumor activities (Duric, Kovac-Besovic et al., 2013, Feng, Yi et al., 2018, Luchnikova, Grishko et al., 2020). Friedelane (OA3) is a natural PT alkane belongs to friedelane triterpenoids (Das, Sarkar et al., 2018). Its skeleton stands behind its efficacy gives rise to be considered as lead molecules for designing anticoronaviral agents (Orhan and Senol Deniz, 2020). Another study reported that 3β-friedelanol has more antiviral activity than that of actinomycin D because of the presence of friedelane skeleton as a scaffold for combinatorial designing of new generation of anti-viral agents for human coronavirus 229E (Chang, Yen et al., 2012). Another study showed that leaf ethanolic extract of Euphorbia neriifolia L. from Taiwan contained one

flavonoid and 22 triterpenoids (Chang, Yen *et al.*, 2012). In this regard, the strongest inhibitor of human coronavirus (229E strain) was  $3\beta$ -friedelanol. As strongly supported by evidence, friedelane triterpenoids possess anti-HIV, anti-microbial, and anti-neoplastic potentials (Das, Sarkar *et al.*, 2018). In this study, OA1, OA2 and OA3 provided equal amount of BA (-13 Kcal/mol) with low toxicity (table 1).

Hopane (OA4) is a triterpene that forms the central nucleus of hopanoids. In this category, hydroxyhopanone has been initially characterized (Van Doelen, 1999). New hopane-type triterpenoids exhibited noteworthy antifungal activity (Zhang, Chen *et al.*, 2019). In this study, OA4 showed BA of -11.0 Kcal/mol with low toxicity (table 1).

Lupane (OA5) with BA of -10.3 Kcal/mol (table 1) is a lupane-type saponin presenting weak cytotoxic activity for Cellosaurus HSC-2 cells (Liu, Zhang et al., 2013). In this line, betulinic and betulin acid and their analogues showed anti-HIV-1 activity at in vitro level (Marciniec, Chrobak et al., 2020). Gammacerane (OA6) with BA of -13.8 Kcal/mol (table 1) is considered an irregular biodegradation-resistant C30 PT (Huang, 2017). Glycyrrhizic acid (OA7; GA) is an oleanane-type triterpenoid with BA of -10.8 Kcal/mol (table 1) which reportedly showed anti-HSV-1 (Herpes simplex virus 1) activity (Ikeda, Yokomizo et al., 2005) and attenuated inflammation in HSV (Huang, Chen et al., 2012). The GA is also derived from β-amyrin type found in liquorice (Glycyrrhiza glabra). Accordingly, GA inhibits different viruses including HIV and hepatitis B virus (HBV) (Pompei, Flore et al., 1979, Xiao, Tian et al., 2018). Moreover, PTs such as glycyrrhizin and 18βglycyrrhetinic acid are considered as a source of flavoring agent and sweetener (Shanmugam, Nguyen et al., 2012). In this line,  $\alpha$  and  $\beta$  stereoisomers of GA express antitumor and anti-inflammatory activities (Shetty, Thirugnanam et al., 2011). The reliable BA of GA with Coronavirus main proteinase (3CLpro) was reported by our team for the first time (Mohammed et al., 2020) however, a seminal study using network pharmacology showed that GA ameliorates cytokine storm response to SARS-CoV-2 (Zheng, Huang et al., 2021). In this essence, lupane, gammacerane and GA belong to high toxicity class III (table 1).

Salaspermic acid (OA8) with BA of -12.5 Kcal/mol (table 1) is toxic oleanane-type triterpene derivative which can inhibit the HIV replication in H9 lymphocytes (Chen, Shi *et al.*, 1992, Xiao, Tian *et al.*, 2018). Betulinic acid (OA9; Bet A) is a PT isolated initially from the birch trees (Bache, Zschornak *et al.*, 2011, Paduch and Kandefer-Szerszen, 2014, Shanmugam, Nguyen *et al.*, 2012). Bet A can express a wide range of anticancer activities for neuroblastoma, melanoma, estrogen receptor negative breast cancer, cervical cancer, colon cancer, ovarian cancer, prostate cancer, and lung cancer (Santos, Salvador

*et al.*, 2011, Suresh, Zhao *et al.*, 2012). Additionally, Bet A can also serve strong antiviral, anti-HIV, antibacterial, anti-inflammatory, anthelmintic, anticancer, and antimalarial activities (Savita, Mishra *et al.*, 2020). The protease of SARS-CoV-2 (PDB ID: 6LU7) is a major player in the viral replication. Results of molecular docking with 6LU7 and its similar structures showed that Bet (A8) had the strongest BA (-11.53 Kcal/mol) among all derivatives (Savita, Mishra *et al.*, 2020). In the present study, Bet A interacted with M<sup>pro</sup> with BA of -11.8 Kcal/mol.

Oleanolic acid (OA10; OA) is one of the most common PTs found in various herbal sources especially prevalent in plants belonging to Oleaceae (olive) family (Fukushima, Seki et al., 2011, Pollier and Goossens, 2012). Among all species of Oleaceae family, olive (Olea europaea L.) (Guinda, Pérez-Camino et al., 2004, Žiberna, Šamec et al., 2017) is still the main source of commercial OA (Sporn, Liby et al., 2011). In these plants, OA is often distributed in epicuticular waxes where it acts as a barrier against water loss and pathogens (Ayeleso et al., 2017). The OA content is much higher in fruit "skin" rather than pulp (Zhang, Daimaru et al., 2013, Žiberna, Šamec et al., 2017). In addition to olives, Mediterranean diet is enriched with OA due to the inclusion of legumes contain OA (0.251 - 2.591)μg/g fresh weight) (Kalogeropoulos, Chiou et al., 2010). A large amount of OA is also present in Ziziphus jujube Mill. which is a routinely consumed fruit in China Southern and Asia (Guo, Duan et al., 2015). Oleanolic acid and its derivatives have antioxidative, antiviral, antiinflammatory and anti-diabetic effects (Sen, 2020). The hepato-protective effects of OA make it a suitable overthe-counter oral drug to treat hepatic diseases such as viral hepatitis in China (Pollier and Goossens, 2012, Reisman, Aleksunes et al., 2009, Wang, Ye et al., 2010). In this line, OA upturns nuclear Nrf2, thereby leading to the induction of Nrf2-dependent genes playing a role in hepato-protection (Klaassen and Reisman, 2010, Reisman, Aleksunes et al., 2009). Moreover, the anticancer effects of OA were reported in the malignancies including hepatocellular cancer (Wang, Bai et al., 2013), breast cancer (Wu, Yang et al., 2016), and lung cancer (Zhao, Liu et al., 2015). The OA-mediated inhibition of tumor growth is widely demonstrated in diverse models. For instance, OA is reported to inhibit the growth of transplanted tumor in mice and proliferation of hepatocellular carcinoma cells (HepG2). The anti-tumor activity of OA is undertaken through upregulating tumor protein (p53), cyclooxygenase-2 mediated activation of mitochondrial apoptotic pathway. Furthermore, OA like acyclovir showed an anti-HSV effect during replication resulting in reduced viral load confirmed by polymerase chain reaction (Mukherjee, Ojha et al., 2013). In the present study, OA interacted with Mpro with BA of -12.6 Kcal/mol. In this line, other study (Kumar, Choudhir et

*al.*, 2021) reported that ursolic acid, carvacrol and OA passed Lipinski's rule of five with reliable BAs for SARS-CoV-2 M<sup>pro</sup>.

3-acetoxy, 28-methyloleanolic acid (OA11) and 3acetoxyoleanolic acid (OA12) are semisynthetic derivatives of OA which possess anti-inflammatory activity and showed erythrocyte membrane-stabilizing properties (Nkeh-Chungag, Oyedeji et al., 2015). The OA11, presented as ligand I in this study (vide infra), showed the strongest BA (-14.2 Kcal/mol) with M<sup>pro</sup>; however, there exist no experimental confirmation supporting its anti-protease or anti-viral activities and further investigations are acknowledged. The interaction between OA12 and Mpro displayed BA of -10.6 Kcal/mol and OA9-OA12 were low (class I) toxic compounds (table 1). The antiviral and antithrombotic activities of OA13 and OA14 have been reported (Khwaza, Oyedeji et al., 2018). Although these two molecules showed good BAs with M<sup>pro</sup>, they were high toxic compounds (table 1). The OA15 to OA30 and OA34 to OA42 showed BAs more than -11.0 Kcal/mol and/or they were toxic compounds; therefore, their anti-viral activities have not been discussed and we would like to seize the readers' attention to a seminal review (Khwaza, Oyedeji et al., 2018) for more information.

The M<sup>pro</sup> (PDB ID: 6Y84) contains three domain I, II, and III containing 8-101, 102-184 and 201-306 amino acid residues, respectively. Domain I and II mainly consists of  $\beta$ -barrels while domain III mainly consists of  $\alpha$ -helix strands. The substrate-binding active site is a cleft between domain I and II which consists of cysteinehistidine catalytic dyad H-41 and C-145 as two catalytic residues. In the present study, OA8, OA13 and saquinavir interacted with M-165, E-166, M-49 and H-41 of Mpro among others while OA37 and OA40 interacted with C-145 in catalytic dyad and M-165 residue in active site (table 2; fig. 3; Supplementary file 1). The OA37 also interacted hydrophobically with M-49 of M<sup>pro</sup> whereas OA-40 employed hydrogen bonds to interact with M<sup>pro</sup>. The majority of binders or inhibitors of Mpro interact at His-41, His-163, His-164, Cys-145, Glu-166, Met-49 and Met-165 residues via aromatic  $\pi$ - $\pi$  stacking and hydrogen bonds (Liu, Jiang et al., 2020). To sum up, OA8, OA13, OA37, OA40 and saquinavir were identified as potential hits employing different interactions with M<sup>pro</sup> (table 2; fig. 3; Supplementary file 1). In addition, OA11 showed strong BA for M<sup>pro</sup> through the interaction with residues R298 using hydrogen bond and an array of similar amino acid residues in comparison with those of OA10 which interacted through hydrophobic interactions. The OA31 in the second order of BA for Mpro also employed Q299 residue in hydrogen bond and a set of amino acids to interact hydrophobically.

We could not present the molecular interactions of OA analogues with all possible targets of SARS-CoV-2, more

investigations are acknowledged to dissect this issue. Based on the structures of PTs, the possibility of chemical promiscuity should be pursued in future studies. Herein, we placed our focus on saquinavir as a counter-reference to compare its *in silico* binding to 3-chymotrypsin (6Y84 PDB) compared to OA analogues links to untangle which phytocompounds could participate in anti-coronoviral effects (table 1). M<sup>pro</sup> is considered one of the key enzymes responsible for the replication and transcription of the coronavirus. Therefore, this study was aimed to explore the activity of these compounds as potent anti-SARS-CoV-2 molecules by employing simulation studies (Wu, Liu *et al.*, 2020).

# CONCLUSION

In current health crisis caused by COVID-19, the identification of novel OA derivatives as potent lead-like or drug-like compounds should be taken into consideration as a novel opportunity. All 42 analogues were subjected to molecular docking against Mpro of SARS-CoV-2. Findings revealed that all compounds showed BAs ranging from -7.7 to -14.2 Kcal/mol having stable interaction with Mpro. However, MD simulation identified OA, ligand I and ligand II as recommended lead-like compounds. Moreover, the identified compounds need to be validated through future studies to more confirmation of their possible anti-SARS-CoV-2 efficacies. To sum up, OA8, OA13, OA37 and OA40 interacted with catalytic dyad and major amino acid residues of active sites of Mpro and these striking features make them suitable candidate for future development of antiviral anti-proteases.

# ACKNOWLEDGMENTS

This work has not been supported financially. The author would like to express his gratitude to the Minister of Higher Education and Scientific Research, Naim Abdel Yasser Al-Aboudi, for their valuable contributions and assistance in improving the quality of this paper.

#### **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# REFERENCES

- Abdulhussein JM, Karimi I, Mohammed LJ and Khan K (2021). The phytobiotic potential of hydro-alcoholic extract of Allium porrum against *Bacillus cereus*: A computational sight into PlcR protein as a putative target. *Biocatal. Agric. Biotechnol.*, **35**: 102062.
- Abraham Dogo G, Uchechukwu O, Umar U, Madaki AJ and Aguiyi JC (2020). Molecular docking analyses of phytochemicals obtained from African antiviral herbal

Pak. J. Pharm. Sci., Vol.38, No.3, May-June 2025, pp.1039-1060

plants exhibit inhibitory activity against therapeutic targets of SARS-CoV-2. J. Genet. Eng. Biotechnol., **4**(3): 410-421

- Acton QA (2013). Immune System Diseases: New insights for the healthcare professional: 2013 Edition: Scholarly Editions pp.US2012077275A1.
- Aghbash PS, Eslami N, Shirvaliloo M. Baghi HB (2021). Viral coinfections in COVID-19. *J. Med. Virol.*, **93**(9): 5310-5322.
- Ahmed HM (2016). Ethnopharmacobotanical study on the medicinal plants used by herbalists in Sulaymaniyah Province, Kurdistan, Iraq. J. ethnobiol. ethnomed., 12(1): 1-17.
- Ali AM and Kunugi H (2021). Propolis, bee honey, and their components protect against coronavirus disease 2019 (Covid-19): A review of in silico, *in vitro* and clinical studies. *Molecules*, **26**(5): 1232.
- Bache M, Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R, Kaluđerović GN, Kommera H and Taubert H (2011). Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. *Radiat. Oncol.*, **6**(1): 1-9.
- Bakhtiyari E, Karimi I. Mohammed LJ Psychobiotics and Thanatophobia: A psychoneuroimmunological insight into microbe-mind modification. *In: Danik M Martirosyan P editor: Functional Foods and Healthy Aging, Food Science Publisher:* pp.7-33.
- Best RB, Zhu X, Shim J, Lopes PE, Mittal J, Feig M and MacKerell Jr AD (2012). Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone  $\phi$ ,  $\psi$  and sidechain  $\chi 1$  and  $\chi 2$  dihedral angles. *J. Chem. Theory Comput.*, **8**(9): 3257-3273.
- Brief TA (2020). Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. *Epidemiology*, 7(1): 1-3.
- Chang FR, Yen CT, Ei-Shazly M, Lin WH, Yen MH, Lin KH and Wu YC (2012). Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of *Euphorbia neriifolia*. *Nat. Prod. Commun.*, **7**(11): 1934578X1200701103.
- Chen K, Shi Q, Fujioka T, Zhang DC, Hu CQ, Jin JQ, Kilkuskie RE and Lee KH (1992). Anti-AIDS agents, Tripterifordin, a novel anti-HIV principle from *Tripterygium wilfordii*: Isolation and structural elucidation. J. Nat. Prod., **55**(1): 88-92.
- Cheng SY, Wang CM, Cheng HL, Chen HJ, Hsu YM, Lin YC and Chou CH (2013). Biological activity of oleanane triterpene derivatives obtained by chemical derivatization. *Molecules*, **18**(10): 13003-13019.
- Chepkwony PK, Medina M and Medina M (2012). Compounds and compositions for treating infection, Google Patents. pp.WO2019232083A1.
- Cramer G, Ford R and Hall R (1976). Estimation of toxic hazard a decision tree approach. *Food Cosmet. Toxicol.*, **16**(3): 255-276.

- Dallakyan S and Olson A J (2015). Small-molecule library screening by docking with PyRx. *Methods Mol. Biol. J.*, **1263**(1): 243-250.
- Darden T, York D and Pedersen L (1993). Particle mesh Ewald: An N. log (N) method for Ewald sums in large systems. J. Chem. Phys., 98(12): 10089-10092.
- Das J, Sarkar A. Ghosh P (2018). Friedelane triterpenoids: transformations toward A-ring modifications including 2-homo derivatives. *New J. Chem.*, **42**(9): 6673-6688.
- Duric K, Kovac-Besovic E, Niksic H and Sofic E (2013). Antibacterial activity of methanolic extracts, decoction and isolated triterpene products from different parts of birch, Betula pendula, Roth. J. Plant Stud., 2(2): 61.
- Essmann U, Perera L, Berkowitz ML, Darden T, Lee H and Pedersen LG (1995). A smooth particle mesh Ewald method. J. Chem. Phys., **103**(19): 8577-8593.
- Fabbri N, Righini E, Cardarelli L, Di Marco L and Feo C (2020). Risks of COVID-19 transmission in blood and serum during surgery A prospective cross-sectional study from a single dedicated COVID-19 center. *Ann. Ital. Chir.*, **91**(3): 235-238.
- Feng J, Yi X, Huang W, Wang Y and He X (2018). Novel triterpenoids and glycosides from durian exert pronounced anti-inflammatory activities. *Food chem.*, 241(1): 215-221.
- Fukushima EO, Seki H, Ohyama K, Ono E, Umemoto N, Mizutani M, Saito K and Muranaka T (2011). CYP716A subfamily members are multifunctional oxidases in triterpenoid biosynthesis. *Plant and Cell Physiol.*, **52**(12): 2050-2061.
- Gianfredi V, Pennisi F, Lume A, Ricciardi GE, Minerva M, Riccò M, Odone A and Signorelli C (2021). Challenges and opportunities of mass vaccination centers in COVID-19 times: A rapid review of literature. *Vaccines*, **9**(6): 574.
- Guinda Á, Pérez-Camino MC and Lanzón A (2004). Supplementation of oils with oleanolic acid from the olive leaf (*Olea europaea*). *Eur. J. Lipid Sci. Technol.*, **106**(1): 22-26.
- Guo S, Duan JA, Qian D, Tang Y, Wu D, Su S, Wang H and Zhao Y (2015). Content variations of triterpenic acid, nucleoside, nucleobase and sugar in jujube (Ziziphus jujuba) fruit during ripening. *Food Chem.*, **167**: pp.468-474.
- Hess B, Bekker H, Berendsen HJ. Fraaije JG (1997). LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem., **18**(12): 1463-1472.
- Hess B, Kutzner C, Van Der Spoel D and Lindahl E (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. *J. Chem. Theory Comput.*, **4**(3): 435-447.
- Hoover WG (1985). Canonical dynamics: Equilibrium phase-space distributions. *Physical review A.*, **31**(3): 1695.
- Huang H (2017). The effect of biodegradation on gammacerane in crude oils. *Biodegradation*, **28**(4): 313-326.

- Huang W, Chen X, Li Q, Li P, Zhao G, Xu M. Xie P (2012). Inhibition of intercellular adhesion in herpex simplex virus infection by glycyrrhizin. *Cell Biochem. Biophys.*, 62(1): 137-140.
- Hung TC, Lee WY, Chen KB. Chen CYC (2014). Lead screening for CXCR4 of the human HIV infection receptor inhibited by traditional Chinese medicine. *Biomed Res. Int.*, **1**(1):809816.
- Ikeda T, Yokomizo K, Okawa M, Tsuchihashi R, Kinjo J, Nohara T and Uyeda M (2005). Anti-herpes virus type 1 activity of oleanane-type triterpenoids. *Biol. Pharm. Bull.*, **28**(9): 1779-1781.
- Kalogeropoulos N, Chiou A, Ioannou M, Karathanos VT, Hassapidou M and Andrikopoulos NK (2010). Nutritional evaluation and bioactive microconstituents (phytosterols, tocopherols, polyphenols, triterpenic acids) in cooked dry legumes usually consumed in the Mediterranean countries. *Food Chem.*, **121**(3): 682-690.
- Kazakova O and Smirnova I (2022). Antiviral activity of lupane and oleanane A-seco-triterpenoids. AIP Conference Proceedings, AIP Publishing LLC. pp.48-50.
- Khanal P, Chikhale R, Dey YN, Pasha I, Chand S, Gurav N, Ayyanar M, Patil B and Gurav S (2022). Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19. *J. Biomol. Struct. Dyn.*, **40**(12): 5295-5308.
- Khwaza V, Oyedeji OO. Aderibigbe BA (2018). Antiviral activities of oleanolic acid and its analogues. *Molecules*, 23(9) 2300.
- Klaassen CD and Reisman SA (2010). Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. *Toxicol. Appl. Pharmacol.*, **244**(1): 57-65.
- Kumar A, Choudhir G, Shukla SK, Sharma M, Tyagi P, Bhushan A and Rathore M (2021). Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. J. Biomol. Struct. Dyn., **39**(10): 3760-3770.
- Laskowski RA and Swindells MB (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, ACS Publications. J. Chem. Inf Model., 51(10): 2778-2786.
- Lipinski CA, Lombardo F, Dominy BW and Feeney PJ (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.*, **23**(1-3): 3-25.
- Liu H, Jiang T, Liu W and Zheng Z (2020). Computational evaluation of the COVID-19 3c-like protease inhibition mechanism and drug repurposing screening.
- Liu J, Zhang J, Wang F, Zou Yf and Chen Xf (2013). Isolation and characterization of new minor triterpenoid saponins from the buds of Lonicera macranthoides. *Carbohydr. Res.*, **370**(1): 76-81.

- Luchnikova NA, Grishko VV and Ivshina IB (2020). Biotransformation of oleanane and ursane triterpenic acids. *Molecules*, **25**(23): 5526.
- Marciniec K, Chrobak E, Dąbrowska A, Bębenek E, Kadela-Tomanek M, Pęcak P and Boryczka S (2020). Phosphate derivatives of 3-carboxyacylbetulin: Synthesis, in vitro anti-HIV and molecular docking study. *Biomolecules*, **10**(8): 1148.
- Matondo A, Kilembe JT, Ngoyi EM, Kabengele CN, Kasiama GN, Lengbiye EM, Mbadiko CM, Inkoto CL, Bongo GN and Gbolo BZ (2021). Oleanolic acid, ursolic acid and apigenin from *Ocimum basilicum* as potential inhibitors of the SARS-CoV-2 main protease: A molecular docking study. *Int. J. Pathog. Res.*, **6**(2): 1-16.
- Mecenas P, Bastos RTdRM, Vallinoto ACR and Normando D (2020). Effects of temperature and humidity on the spread of COVID-19: A systematic review. *PLoS one*, **15**(9): e0238339.
- Mohammed HNM, Layth Jasim, Karimi Isaac and Suvitha A (2020). A computational effort to deciphering putative COVID-19 3C-like protease binders in the selected recipes of Kurdish ethnomedicine: An approach to find an antiviral functional Tea. *In*: Danik M Martirosyan P Editor. *functional Foods and Viral Diseases*, Food Science Publisher. pp.69-90.
- Mukherjee H, Ojha D, Bag P, Chandel HS, Bhattacharyya S, Chatterjee TK, Mukherjee PK, Chakraborti S. Chattopadhyay D (2013). Anti-herpes virus activities of Achyranthes aspera: An Indian ethnomedicine, and its triterpene acid. *Microbiol. Res.*, **168**(4): 238-244.
- Munro IC, Ford RA, Kennepohl E and Sprenger JG (1996). Correlation of structural class with noobserved-effect levels: A proposal for establishing a threshold of concern. *Food Chem. Toxicol.*, **34**(9): 829-867.
- Nikhra V (2021). Evolving patterns in COVID-19: The virus, its variants and infectivity-cum-virulence. *Biomed. J. Sci. Tech. Res.*, **33**(2): 25712-25722.
- Nkeh-Chungag BN, Oyedeji OO, Oyedeji AO and Ndebia EJ (2015). Anti-inflammatory and membranestabilizing properties of two semisynthetic derivatives of oleanolic acid. *Inflammation*, **38**(1): 61-69.
- Nose S (1984). A molecular dynamics method for simulations in the canonical ensemble. *Mol. Phys.*, **52**(2): 255-268.
- Nosé S and Klein M (1983). Constant pressure molecular dynamics for molecular systems. *Mol. Phys.*, **50**(5): 1055-1076.
- Orhan IE and Senol Deniz FS (2020). Natural products as potential leads against coronaviruses: Could they be encouraging structural models against SARS-CoV-2? *Nat. prod. bioprospect.*, **10**(4): 171-186.
- Paduch R and Kandefer-Szerszen M (2014). Antitumor and antiviral activity of pentacyclic triterpenes. *Mini-Rev. Org. Chem.*, **11**(3): 262-268.

- Parrinello M and Rahman A (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl. Phys.*, **52**(12): 7182-7190.
- Patlewicz G, Jeliazkova N, Safford R, Worth A and Aleksiev B (2008). An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. *SAR QSAR Environ. Res.*, **19**(5-6): 495-524.
- Pawełczyk A and Zaprutko L (2020). Anti-COVID drugs: Repurposing existing drugs or search for new complex entities, strategies and perspectives. *Future Med. Chem.*, **12**(19): 1743-1757.
- Pollier J and Goossens A (2012). Oleanolic acid. *Phytochemistry*, **77**(1): 10-15.
- Pompei R, Flore O, Marccialis MA, Pani A and Loddo B (1979). Glycyrrhizic acid inhibits virus growth and inactivates virus particles. *Nature*, **281**(5733): 689-690.
- Redmond SN, Jones LD, Sadri N, Schmotzer C, Navas ME, Zabarsky TF, Bhullar D and Donskey CJ (2022). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans' Affairs healthcare system. *Infect. Control Hosp. Epidemiol.*, **43**(9): 1300-1301.
- Reisman SA, Aleksunes LM and Klaassen CD (2009). Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. *Biochem. Pharmacol.*, **77**(7): 1273-1282.
- Rivail L, Chipot C, Maigret B, Bestel I, Sicsic S and Tarek M (2007). Large-scale molecular dynamics of a G protein-coupled receptor, the human 5-HT4 serotonin receptor, in a lipid bilayer. J. Mol. Struct. THEOCHEM., **817**(1-3): 19-26.
- Ruzicka L (1953). The isoprene rule and the biogenesis of terpenic compounds. *Experientia.*, **9**(10): 357-367.
- Santos RC, Salvador JA, Cortés R, Pachón G, Marín S and Cascante M (2011). New betulinic acid derivatives induce potent and selective antiproliferative activity through cell cycle arrest at the S phase and caspase dependent apoptosis in human cancer cells. *Biochimie*, **93**(6): 1065-1075.
- Savita S, Mishra S and Jaiswal K (2020). Molecular docking studies of betulinic acid and its structurally modified derivatives as potential inhibitors of COVID-19 main protease protein. *Biochem. Cell. Arch.*, 20(10):4503-4510.
- Sen A (2020). Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases. *World J. Clin. Cases*, 8(10): 1767.
- Shanmugam MK, Nguyen AH, Kumar AP, Tan BK and Sethi G (2012). Targeted inhibition of tumor proliferation, survival and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer. *Cancer lett.*, **320**(2): 158-170.
- Shetty AV, Thirugnanam S, Dakshinamoorthy G, Samykutty A, Zheng G, Chen A, Bosland MC,

Kajdacsy-Balla A and Gnanasekar M (2011).  $18\alpha$ glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. *Int. J. Oncol.*, **39**(3): 635-640.

- Shi H, Ren K, Lv B, Zhang W, Zhao Y, Tan RX. Li E (2016). Baicalin from *Scutellaria baicalensis* blocks respiratory syncytial virus (RSV) infection and reduces inflammatory cell infiltration and lung injury in mice. *Sci. rep.*, 6(1): 1-12.
- Siddique HR. Saleem M (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. *Life sci.*, **88**(7-8): 285-293.
- Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM and Gribble GW (2011). New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod., 74(3): 537-545.
- Su Y, Meng L, Sun J, Li W, Shao L, Chen K, Zhou D, Yang F and Yu F (2019). Design, synthesis of oleanolic acid-saccharide conjugates using click chemistry methodology and study of their anti-influenza activity. *Eur. J. Med. Chem.*, **182**: 111622.
- Suresh C, Zhao H, Gumbs A, Chetty CS and Bose HS (2012). New ionic derivatives of betulinic acid as highly potent anti-cancer agents. *Bioorg. Med. Chem. Lett.*, **22**(4): 1734-1738.
- Thomsen R and Christensen MH (2006). MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem., **49**(11): 3315-3321.
- Van Asten L, Harmsen CN, Stoeldraijer L, Klinkenberg D, Teirlinck AC, De Lange MM, Meijer A, Van De Kassteele J, van Gageldonk-Lafeber AB and Van Den Hof S (2021). Excess deaths during influenza and corona virus disease and infection-fatality rate for severe acute respiratory syndrome coronavirus 2, the Netherlands. *Emerg. Infect. Dis.*, **27**(2): 411.
- Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE and Berendsen HJ (2005). GROMACS: Fast, flexible and free. *J. Comput. Chem.*, **26**(16): 1701-1718.
- Van Doelen G (1999). Molecular studies of fresh and aged triterpenoid varnishes, Ph.D Thesis, University of Amsterdam. pp.137-56.
- Vanommeslaeghe K and MacKerell Jr AD (2012). Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing. J. Chem. Inf. Model., **52**(12): 3144-3154.
- Villamagna AH, Gore SJ, Lewis JS and Doggett JS (2020). The need for antiviral drugs for pandemic coronaviruses from a global health perspective. *Front. Med.*, **22**(7): 596587
- Voigt K, Nahimana E and Rosenthal A (2021). Flashing red lights: The global implications of COVID-19

vaccination passports. *BMJ Glob. Health*, **6**(5): e006209.

- Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z and Hai C (2013). Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERKp53-mediated cell cycle arrest and mitochondrialdependent apoptosis. *Carcinog.*, 34(6): 1323-1330.
- Wang X, Ye XI, Liu R, Chen HL, Bai H, Liang X, Zhang XD, Wang Z, Li Wl and Hai CX (2010). Antioxidant activities of oleanolic acid *in vitro*: Possible role of Nrf2 and MAP kinases. *Chem. Biol. Interact.*, 184(3): 328-337.
- Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M and Li X (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica. B.*, **10**(5): 766-788.
- Wu J, Yang C, Guo C, Li X, Yang N, Zhao L, Hang H, Liu S, Chu P and Sun Z (2016). SZC015, a synthetic oleanolic acid derivative, induces both apoptosis and autophagy in MCF-7 breast cancer cells. *Chem. Biol. Interact.*, 244(1): 94-104.
- Wu TS (2004). Herbal pharmaceutical composition for treatment of HIV/AIDS patients, Google Patents. pp. 6,696,094.
- Xiao S, Tian Z, Wang Y, Si L, Zhang L and Zhou D (2018). Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. *Med. Res. Rev.*, **38**(3): 951-976.
- Zhang F, Daimaru E, Ohnishi M, Kinoshita M. Tokuji Y (2013). Oleanolic acid and ursolic acid in commercial dried fruits. *Food Sci. Technol. Res.*, **19**(1): 113-116.
- Zhang X, Chen HL, Hong L, Xu LL, Gong XW, Zhu DL, Xu XH, Zhao W, Wang F and Yang XL (2019). Three new hopane-type triterpenoids from the aerial part of Adiantum capillus-veneris and their antimicrobial activities. *Fitoterapia.*, **133**(1): 146-149.
- Zhao X, Liu M and Li D (2015). Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. *Mol. Cell. Biochem.*, 400(1): 1-7.
- Zheng W, Huang X, Lai Y, Liu X, Jiang Y and Zhan S (2021). Glycyrrhizic Acid for COVID-19: Findings of Targeting Pivotal Inflammatory Pathways Triggered by SARS-CoV-2. *Front. Pharmacol.*, **12**(1): 631206.
- Žiberna L, Šamec D, Mocan A, Nabavi SF, Bishayee A, Farooqi AA, Sureda A and Nabavi SM (2017). Oleanolic acid alters multiple cell signaling pathways: implication in cancer prevention and therapy. *Int. J. Mol. Sci.*, **18**(3): 643.